• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cellular physiology. >Molecular and clinical characterization of Galectin-9 in glioma through 1,027 samples
【24h】

Molecular and clinical characterization of Galectin-9 in glioma through 1,027 samples

机译：分子和临床特征通过1027个样本Galectin-9在神经胶质瘤

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In recent years, research on glioma immunotherapy have grown rapidly. However, the autoimmune-like side effects that are caused by blocking immunological checkpoints hinder their clinical application in gliomas currently. Galectin-9, a ligand for T-cell immunoglobulin mucin 3, has shed a new light on the treatment of malignant glioma. However, the potential mechanism of Galectin-9 is still under discussion. In this study, first, we methodically gathered 1,027 glioma patients with RNA-seq and 986 patients with survival data to explore the role and mechanism of Galectin-9 in gliomas. Second, we analyzed glioma samples from 50 patients in the Department of Neurosurgery, Tianjin Medical University General Hospital. Finally, we found that Galectin-9 was strongly upregulated in glioblastoma multiforme compared with normal brain tissues and lower-grade glioma. Patients with Galectin-9 overexpression had a significantly shorter overall survival. Moreover, the tissue microarray data displayed that the expression of Galectin-9 in the core of tumor is higher than that in the border and was correlated with the shorter survival in glioma patients. Galectin-9 is more highly expressed in the mesenchymal subtype of glioblastoma multiforme than in the other subtypes. Simultaneously, Galectin-9 was closely associated with the immune response and lymphocyte activation, especially T-cell activation. To further determine the underlying role of Galectin-9 in the immune response, we selected seven immune metagenes. Through cluster analysis and correlation analysis, we discovered that Galectin-9 was highly correlated with immune checkpoint molecules and M2 tumor-associated macrophages. In summary, Galectin-9 serves as a potential therapeutic target to treat glioblastoma multiforme.
机译：近年来,神经胶质瘤免疫治疗研究生长得快。副作用是由阻塞引起的阻碍他们的临床免疫学的检查点目前应用在神经胶质瘤。配体对t细胞免疫球蛋白粘蛋白3把一缕新的光束照在恶性肿瘤的治疗神经胶质瘤。Galectin-9仍在讨论中。研究中,首先,我们1027年有条不紊地聚集神经胶质瘤患者RNA-seq和986名患者生存数据探索和扮演的角色在神经胶质瘤Galectin-9机制。分析了50个病人的神经胶质瘤样本神经外科学系、天津医学大学综合医院。Galectin-9强烈调节多形性成胶质细胞瘤与正常相比大脑神经胶质瘤组织和品位。与Galectin-9过度了总生存期短得多。组织微阵列数据的显示Galectin-9的表达在肿瘤的核心高于在边境,是相关的与短神经胶质瘤患者的生存。Galectin-9中高度表达间叶细胞的多形性成胶质细胞瘤亚型比其他亚型。Galectin-9与免疫密切相关响应和淋巴细胞活化,尤其是t细胞激活。底层Galectin-9在免疫中的作用反应,我们选择七metagenes免疫。通过聚类分析和相关性分析,我们发现Galectin-9与免疫检查点高度相关分子和M2肿瘤相关巨噬细胞。总结,Galectin-9作为潜力治疗胶质母细胞瘤的治疗目标multiforme .

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号